Dexamethasone 2mg Tablets
Sponsors
Celgene Corp., Glaxosmithkline Research & Development Limited, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Regeneron Pharmaceuticals Inc., Amgen Inc.
Conditions
Multiple MyelomaPreviously treated locally advanced and unresectable or metastatic
non-small cell lung cancer (NSCLC) with KRAS p.G12C mutationRelapsed or Refractory Multiple Myeloma (RRMM)Relapsed or Refractory Systemic Light Chain AmyloidosisRelapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)Relapsed/Refractory Multiple Myeloma
Phase 1
A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis
RecruitingCTIS2023-507809-34-00
Start: 2024-08-07Target: 27Updated: 2025-09-24
A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruitingCTIS2023-505219-19-00
Start: 2019-09-03Target: 86Updated: 2025-09-03
A Phase 1b/2a Multicenter, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma
Active, not recruitingCTIS2024-510799-19-00
Start: 2016-08-09Target: 221Updated: 2025-08-08
Phase 3
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Active, not recruitingCTIS2023-508214-42-00
Start: 2020-05-25Target: 362Updated: 2025-09-22
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
Not yet recruitingCTIS2023-507632-20-00
Target: 440Updated: 2026-01-13
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Active, not recruitingCTIS2023-510537-28-00
Start: 2020-05-15Target: 203Updated: 2025-10-30
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Active, not recruitingCTIS2023-506877-37-00
Start: 2020-09-28Target: 148Updated: 2025-12-15
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
Active, not recruitingCTIS2024-510800-35-00
Start: 2022-06-17Target: 394Updated: 2026-01-08